Navigation Links
Mylan to Speak at the Bank of America Merrill Lynch Global Healthcare Conference
Date:9/5/2013

PITTSBURGH, Sept. 5, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that Chief Financial Officer John Sheehan will speak at the Bank of America Merrill Lynch Global Healthcare Conference on Thursday Sept. 12, 2013 at 1 p.m. BST, 8 a.m. EDT, at the Bank of America Merrill Lynch Financial Centre, London, UK. The conference will be webcast live and can be accessed on Mylan's Investor Relations Web site at http://investor.mylan.com/.

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same location for a limited time.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vt.
2. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
3. Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
4. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
5. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
6. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
7. Roger Graham Named President of Mylan Specialty
8. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
9. Mylan to Speak at the Goldman Sachs 34th Annual Global Healthcare Conference
10. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
11. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Research and Markets has announced the addition of ... offering. ... This report analyzes the worldwide markets for Endodontic Supplies in US$ Thousand. ... , Japan , Europe , ... Annual estimates and forecasts are provided for the period 2015 through ...
(Date:12/8/2016)... 8, 2016   TriNetX , the health ... Hospital signed a membership agreement to join ... of new cures. The TriNetX network ... million patients globally, biopharmaceutical companies and contract research ... protocol design, site selection, patient recruitment, and collaborative ...
(Date:12/8/2016)... LAVAL, Quebec , Dec. 8, 2016 /PRNewswire/ ... and TSX: VRX) ("Valeant") today announced positive ... vehicle-controlled clinical study to assess the safety and ... in the treatment of plaque psoriasis. ... adult subjects with moderate to severe psoriasis, IDP-118 ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... "I had a terrible time trying to get my grandson ... if the nebulizer had a more child-friendly design, then children would be more likely ... patent-pending NEBY to avoid the need to deliver medication via a nebulizer mask. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
(Date:12/8/2016)... NY (PRWEB) , ... December 08, 2016 , ... ... is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods ... in JMIR Medical Informatics . , Results of the comparative usability study ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
Breaking Medicine News(10 mins):